A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

NCT02561871 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Viruses
Respiratory Tract Infections

Interventions

BIOLOGICAL: Ad26.RSV.FA2
BIOLOGICAL: Ad35.RSV.FA2
DRUG: Placebo

Sponsor

Crucell Holland BV